Riluzole is an oral benzothiazole-class therapy indicated for amyotrophic lateral sclerosis (ALS). U.S. labeling for the brand RILUTEK lists initial FDA approval in 1995. The therapeutic mechanism in ALS is not fully established in the labeling.
A Delphi consensus of 23 experts identified Zostavax, sildenafil and riluzole as high-priority candidates for Alzheimer disease clinical trials. Caregivers ranked the herpes zoster vaccine highest for acceptability and perceived benefit–risk balance.
A phase 3 clinical trial has launched for pridopidine as a potential ALS treatment, while AI research identified 18 FDA-approved drugs that may extend survival. Separate studies found a promising three-drug combination for sporadic ALS using new cell models.
PrimeC, an oral combination therapy, showed safety and signals of clinical benefit in a phase 2b trial, while PLL001, a gut-targeting therapy, demonstrated positive safety and tolerability in a phase I/II study for amyotrophic lateral sclerosis.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07447050 |
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial |
RECRUITING | PHASE2 |
| NCT07414212 |
Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS) |
RECRUITING | PHASE1/PHASE2 |
| NCT06676423 |
Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS |
COMPLETED | PHASE1 |
| NCT06580002 |
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial |
RECRUITING | PHASE2 |
| NCT06270108 |
The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia |
RECRUITING | EARLY_PHASE1 |
| NCT04761614 |
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer |
COMPLETED | PHASE1 |
| NCT04745299 |
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS |
COMPLETED | PHASE3 |
| NCT04630444 |
Riluzole Effects on Hippocampus Biomarkers |
COMPLETED | EARLY_PHASE1 |
| NCT04454840 |
Treatment of Intravenous Infusion Plasma in Amyotrophic Lateral Sclerosis |
COMPLETED | EARLY_PHASE1 |
| NCT03722680 |
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy. |
SUSPENDED | PHASE2 |
